We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800 Open access books available
116,000 International authors and editors
120M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
The Epidemiology of Vascular Dementia

Demet Ozbabalı, Didem Arslantaş and Nese Tuncer Elmacı

1Eskisehir Osmangazi University, Medical Faculty, Department of Neurology, Eskisehir, Turkey
2Marmara University, Medical Faculty, Department of Neurology, Istanbul, Turkey
3Eskisehir Osmangazi University, Medical Faculty, Department of Public Health, Eskisehir, Turkey

1. Introduction

Average life expectancy in the world is getting longer in the developing countries as well as developed countries. This means that we will encounter some of the diseases more than diseases which are only seen in elderly, in the coming years. Dementia is one of the most important health problems of the elderly population today, up to the developed countries is seen as a major threat in developing countries. WHO projections suggest that by 2025, about three-quarters of the estimated 1.2 billion people aged 60 years and older will reside in developing countries (1). Thus, by 2040, if growth in the older population continues, 71% of 81.1 million dementia cases will be in the developing world (Figure 1) (2).

Epidemiology is the study of health-event patterns in a society (3). It is the cornerstone method of public health research, and helps inform evidence-based medicine for identifying risk factors for disease and determining optimal treatment approaches to clinical practice and for preventive medicine. Epidemiologic measures are named as two types; incidence and prevalence. Whereas incidence deals with what is new, prevalence deals with what exists. By definition, prevalence is the number of cases of a given disease that exists in a defined population at a specified time. Incidence represents new event.

Dementia is actually a syndrome. It may be caused by various underlying diseases, each characterized by specific clinical features and neuropathology. Alzheimer disease (AD) which is a neurodegenerative is the most prevalent cause of dementia. The neuropathology of disease include in neuritic plaques and neurofibrillary tangle in the brain. Vascular dementia (VaD), describing impairments in cognitive function caused by problems in cerebral or cardiac blood vessels, is the second most common cause of dementia after Alzheimer disease in the aging population (Figure 2) (4). It comprises 10-20 % of all dementia. A meta-analysis of the European studies on incidence of dementia showed that VaD constitute 17.6 % of all dementia (5). In Europe and North America, AD is more common than VaD in a 2:1 ratio; in contrast in Japan and China VaD accounts for almost 50 % of all dementia (6, 13).

Vascular dementia is a complex disease and a common complication resulting from a blocked blood vessel causing a stroke. The most common mechanisms underlying VaD are...
multiple large-vessel infarcts, a single strategically placed infarct (angular gyrus, thalamus, basal forebrain, posterior cerebral artery or anterior cerebral artery), multiple basal ganglia and white matter lacunes, or extensive periventricular white-matter lesions. The most commonly encountered subtype of VaD is extensive periventricular white-matter lesions. Multiple large vessel infarcts and others follow up them (14).

Vascular dementia is historically reflected by the diagnoses of “dementia with stroke” or “multi-infarct dementia,” although these terms have been replaced with the broader concepts of vascular dementia and vascular cognitive impairment, recognizing the contribution to dementia of all vascular disease. Pathological findings have shown that much dementia cannot be attributed to a single underlying cause but arises from a combination of factors among which cerebrovascular disease, including infarct and haemorrhage, is an important contributor.

Although the incidence and prevalence of dementia are increasing, determining the incidence and prevalence of dementia is difficult (15-20).

Even with the difficulties of detecting and defining to prevalence and incidence in the population, it is clear that dementia causes a substantial burden on societies. There is an urgent need to develop preventive strategies and to identify of modifiable risk factors about each type of dementia. Newer imaging techniques and neuropsychological test batteries provide an opportunity to identify subclinical manifestations of “dementias” that can be limited to the risk factors and subsequent clinical disease. Problems with diagnostic inaccuracy and insidious disease onset influence results of the epidemiologic studies (21).
Epidemiologic studies of VaD have been also affected by variations in the definition of the disorders, the clinical criteria used and the methods. Analysis of data from 12 centres for which imaging findings were available indicates that 26% of cases of dementia fulfilled the US National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l’Enseignement en Neurosciences (NINDS–AIREN) criteria for VaD (22,23).

2. Prevalence and incidence

Prevalence estimates vary highly between studies because of methodological and geographical differences (Table 1) (24). However, the prevalence of VaD ranges from one to four percent in people over the age of 65 and seems to be higher in China and Japan than in Europe and North America. While the rate is 1.5% in Western countries and in Japan is approximately 2.2%. In Japan, vascular dementia accounts for 50% of all dementias that occur in individuals older than 65 years. In Europe, vascular dementia and mixed dementia account for approximately 20% and 40% of cases, respectively (25-28).

In 2000, prevalence data from 11 European population based studies were pooled to obtain stable estimates of prevalence of dementia in the elderly (>65 years). Age standardised prevalence was 6.4% for dementia (all causes), and 1.6% for VaD (29). In clinical studies, the prevalence of VaD ranges from 4.4% and 39%, its incidence from 0.42 to 2.65, with doubling every 5 years in western memory clinical and population based series. In Asia, a number of studies on the prevalence of dementia have been published in Chinese, yielding varied results. By comparison with these studies that reported a prevalence range of VaD as 0.2 % to 2.7 %, respectively for those aged 60 years and older (30).
Data suggests that the annual incidence of VaD may range from 20-40 per 100,000 between persons 60-69 years old to 200-700 per 100,000 in persons over age 80.

Table 1. Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. J Alzheimers Dis. 2009 (The Turkish data was added).

<table>
<thead>
<tr>
<th>Year</th>
<th>Criteria</th>
<th>Sample size (n)</th>
<th>Age (years)</th>
<th>Prevalence (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All dementia</td>
</tr>
<tr>
<td>Asia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>2007</td>
<td>DSM-III, ICD-10</td>
<td>&gt;65</td>
<td>3.1% (2.8–3.5)</td>
</tr>
<tr>
<td>China</td>
<td>2005</td>
<td>DSM-IV</td>
<td>34 807</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Taiwan</td>
<td>1995-1998</td>
<td>DSM-III, DSM-IV</td>
<td>7149</td>
<td>&gt;65</td>
</tr>
<tr>
<td>South Korea</td>
<td>1994-2005</td>
<td>DSM-III, DSM-IV</td>
<td>7096</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Thaiian</td>
<td>2001</td>
<td>DSM-III</td>
<td>4048</td>
<td>&gt;60</td>
</tr>
<tr>
<td>India</td>
<td>1996-2006</td>
<td>DSM-III, DSM-IV</td>
<td>14 767</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>2003</td>
<td>DSM-IV</td>
<td>703</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Israel</td>
<td>2002</td>
<td>DSM-IV</td>
<td>823</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Turkey</td>
<td>2009</td>
<td>DSM-IV</td>
<td>5100</td>
<td>&gt;55</td>
</tr>
<tr>
<td>Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Egypt</td>
<td>1998</td>
<td>DSM-IV</td>
<td>1366</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Nigeria</td>
<td>1995</td>
<td>DSM-III, ICD-10</td>
<td>2494</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Latin America</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cuba</td>
<td>1999</td>
<td>DSM-IV</td>
<td>799</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Argentina</td>
<td>1999</td>
<td>DSM-IV</td>
<td>1900</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Brazil</td>
<td>2002-2008</td>
<td>DSM-III, DSM-IV</td>
<td>7513</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Chile</td>
<td>1997</td>
<td>DSM-III</td>
<td>2213</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Colombia</td>
<td>2000</td>
<td>DSM-IV</td>
<td>1611</td>
<td>&gt;65 and &gt;75</td>
</tr>
<tr>
<td>Peru</td>
<td>2007</td>
<td>DSM-IV</td>
<td>1532</td>
<td>&gt;65</td>
</tr>
<tr>
<td>Venezuela</td>
<td>2002</td>
<td>DSM-IV</td>
<td>2438</td>
<td>&gt;55 and &gt;65</td>
</tr>
</tbody>
</table>
3. Age and gender

Studies show that the occurrence of VaD exponentially increases with age from 65 to 85 years. The prevalence of dementia of all causes increases between the seventh and tenth decade from 0.8 to 28.5% that of vascular dementia (VD) (15.8% of total) from 0.3 to 5.2% or from 0.2 to 16% over age 80. In 2030, nearly 70 million patients with dementia is expected in 65 and older populations, without any substantial difference between men and women. Under eighty-five years of age the prevalence of VaD was higher in men compared to women and thereafter the prevalence was higher in women (29). In a longitudinal community survey of Japanese American men (Honolulu Asia Aging Study), 23% of vascular dementia was attributed. to large-vessel, 50% to small-vessel, and 16% to mixed-vessel disease (31).

The age-standardized prevalence of VaD was 1.6% and also increased with age. However, contrary to AD, the difference in prevalence between men and women was age dependent. This finding might also be attributed to differences in survival between men and women. However, it may also reflect changes in incidence pattern.

4. Variation across region

There are differences amongst cultural, demographic and ethnic variability in incidence and prevalence studies. The proportion of AD and VaD dementia was different from that in Europe and other Asian countries. For example, VD tends to be more common than AD in Japan and Russia (31-32). Even, a marked geographical dissociation in Europe between the north and south, linked to differences in vascular risk factors has been proposed to account for the higher incidence rates in the oldest-old of north-western countries (Finland, Sweden, Denmark, the Netherlands, and the United Kingdom) compared to southern countries (France and Spain). This difference is further supported by north–South regional findings of differences in MRI-detected white matter lesion (WML) pathology. Greater WML pathology linked to progression of dementia has been observed in southern Europe relative to northern and central European countries (33,35).

Few studies reported the differences in the distribution of dementia subtypes between rural and urban areas. Interestingly, they found that there was a significantly higher prevalence of Alzheimer disease in the rural area than the urban area. And on the contrary, there was a higher prevalence of vascular dementia in the urban area than the rural area. It may be owing to the differences in education levels, socioeconomic status, obesity and body mass index, diet, and life style between the two areas. If the future studies continue to report the higher prevalence of vascular dementia in urban areas, it means that there will be increased demands on healthcare system particularly among urban populations (36-40).

5. Family history and genetic

Dementia risk can increase two- to four-fold among individuals who have at least one first degree relative with dementia. Genetic factors play an important role in the aetiology of VaD. However, there is less epidemiological evidence for a genetic component of risk factors of VaD like cardio embolic stroke. Two known genetic disease can be thought that VaD have genetic characteristics. These are cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukencephalopathy (CADASIL: a subcortical small vessel disease accompanied by lacunars’ strokes, migraine, and dementia) and hereditary cerebral haemorrhage with amyloidosis- Dutch type (HCHWA-D) (41).

The CADASIL condition is a heritable small-vessel disease caused by mutations in NOTCH3 gene which is normally expressed in vascular smooth muscle cells and pericytes (including those of the cerebral vasculature) and that encodes a cell-surface receptor, which has a role in arterial development and is expressed on vascular smooth-muscle cells. About 95% of patients have missense mutations that cluster in exons 3, but the pathogenic mechanism is still unknown. With regard to HCHWA-D (a syndrome of primarily hemorrhagic strokes and dementia), it is caused by a mutation in the gene for amyloid precursor protein (APP) that causes abnormal deposition of amyloid in the walls of leptomeningeal arteries and cortical arterioles, it is known as cerebral amyloid angiopathy (CAA) (42).

The studies using the candidate gene approaches has identified a number of genetic variants possibly involved in risk factor development. They can contribute to conventional risk factors such as hypertension, diabetes, or homocysteine concentrations. Recently, APO E4 was studied in VaD after AD as risk factors. As authors, VaD risk also increases with the number of alleles: homozygous carriers are at a greater risk than heterozygous carriers or those who do not carry the E4 variant (43, 44).

A study showed that MAPT (microtubule-associated protein tau) was associated with VaD and since MAPT is a gene playing an important role in AD. Moreover, G allele of rs1467967 is the risk allele, which is the major allele in Chinese population (45).

6. Hypertension and other vascular risk factors

Mid-life hypertension (high blood pressure) has been associated with impaired cognitive function even in otherwise healthy individuals (46). Traditionally VaD has been considered affected by hypertension and the alleviation of it. In a Japan study, the age- and sex-adjusted incidence of VaD significantly increased with elevated late-life blood pressure levels whereas no such association was observed for Alzheimer disease. The current meta-analysis highlights the potential importance of rigorous treatment of hypertension as a key measure to help prevent the development of VaD (47).

Except hypertension, histories of diabetes, metabolic syndrome, hyperlipidemia, myocardial infarction/cardiatic decomposition, heavy smoking, obesity and a history of stroke are other risk factors for VaD. The Cardiovascular Health Cognition Study developed a late-life dementia risk index that included older age, worse cognitive test performance, lower body mass index (BMI), APOE 4 allele, MRI findings of white matter disease or ventricular enlargement, internal carotid artery thickening on ultrasound, history of bypass surgery, slower physical performance, and lack of alcohol consumption (48).

7. Lifestyle

Risk finding for alcohol is not consistent. Alcohol has been found to have a protective effect in moderate drinkers with a five-fold increase in dementia in both abstainers and those who drink heavily. A study found a link between increasing alcohol consumption and VaD (49).
In some studies alcohol and smoking are neither strongly protective nor predictive (50). In some studies were informed that high educational attainment, eating fish or shellfish, physical exercise, use of supplementary antioxidants like beta-carotene, omega-3, Vitamins E and C, use of Vitamin B12, Mediterranean diet might be potential protective factors for VaD (51,53).

8. Conclusion remarks
1. Vascular dementia (VaD) is the second most common cause of dementia after Alzheimer disease in the aging population.
2. Prevalence estimates vary highly between studies because of methodological and geographical differences.
3. Prevalence rate is 1.5% in Western countries and in Japan is approximately 2.2%.
4. Annual incidence of VaD may range from 20-40 per 100000 between persons 60-69 years old to 200-700 per 100.000 in persons over age 80.
5. There are differences amongst cultural, demographic and ethnic variability in incidence and prevalence studies.
6. Sex patterns remain unclear for prevalence and incidence.
7. Dementia risk can increase two- to four-fold among individuals who have at least one first degree relative with dementia.
8. Hypertension, histories of diabetes, metabolic syndrome, hyperlipidemia, myocardial infarction/cardiac decomposition, heavy smoking, obesity and a history of stroke are other risk factors for VaD.
9. Finally, about epidemiology of VaD is not clear as well as AD. We need more studies in the world.

9. References


The Epidemiology of Vascular Dementia


www.intechopen.com


With the baby boomer generation reaching 65 years of age, attention in the medical field is turning to how best to meet the needs of this rapidly approaching, large population of geriatric individuals. Geriatric healthcare by nature is multi-dimensional, involving medical, educational, social, cultural, religious and economic factors. The chapters in this book illustrate the complex interplay of these factors in the development, management and treatment of geriatric patients, and begin by examining sarcopenia, cognitive decline and dysphagia as important factors involved in frailty syndrome. This is followed by strategies to increase healthspan and lifespan, such as exercise, nutrition and immunization, as well as how physical, psychological and socio-cultural changes impact learning in the elderly. The final chapters of the book examine end of life issues for geriatric patients, including effective advocacy by patients and families for responsive care, attitudes toward autonomy and legal instruments, and the cost effectiveness of new health care technologies and services.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
